Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by OMERS ADMINISTRATION Corp

OMERS ADMINISTRATION Corp decreased its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 8.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,742 shares of the pharmaceutical company's stock after selling 1,213 shares during the period. OMERS ADMINISTRATION Corp's holdings in Vertex Pharmaceuticals were worth $5,534,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. Brown Lisle Cummings Inc. purchased a new position in shares of Vertex Pharmaceuticals in the 4th quarter worth $30,000. Sugar Maple Asset Management LLC purchased a new stake in Vertex Pharmaceuticals during the fourth quarter valued at approximately $35,000. Golden State Wealth Management LLC bought a new stake in shares of Vertex Pharmaceuticals in the 4th quarter valued at approximately $37,000. Truvestments Capital LLC boosted its holdings in shares of Vertex Pharmaceuticals by 30.3% in the 4th quarter. Truvestments Capital LLC now owns 99 shares of the pharmaceutical company's stock worth $40,000 after purchasing an additional 23 shares during the period. Finally, Midwest Capital Advisors LLC bought a new position in shares of Vertex Pharmaceuticals during the 4th quarter valued at approximately $41,000. 90.96% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on VRTX shares. Wells Fargo & Company lowered shares of Vertex Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $460.00 target price for the company. in a report on Thursday, January 30th. HC Wainwright restated a "buy" rating and issued a $550.00 price target on shares of Vertex Pharmaceuticals in a report on Tuesday, February 11th. StockNews.com upgraded shares of Vertex Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Tuesday, March 11th. Truist Financial upped their target price on shares of Vertex Pharmaceuticals from $460.00 to $520.00 and gave the stock a "buy" rating in a research note on Tuesday, February 11th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Vertex Pharmaceuticals in a report on Tuesday, May 6th. Thirteen investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $515.04.

Vertex Pharmaceuticals Stock Performance

Vertex Pharmaceuticals stock traded up $4.27 during mid-day trading on Friday, hitting $438.65. The company had a trading volume of 1,505,089 shares, compared to its average volume of 1,409,926. The company's fifty day moving average is $482.97 and its 200-day moving average is $464.51. Vertex Pharmaceuticals Incorporated has a 12-month low of $377.85 and a 12-month high of $519.88. The company has a market capitalization of $112.64 billion, a price-to-earnings ratio of -199.39, a P/E/G ratio of 2.11 and a beta of 0.51. The company has a current ratio of 2.69, a quick ratio of 2.35 and a debt-to-equity ratio of 0.01.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share for the quarter, missing the consensus estimate of $4.29 by ($0.23). The company had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.85 billion. Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. The firm's revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter last year, the company earned $4.76 EPS. Equities research analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Insider Activity

In other news, EVP Ourania Tatsis sold 530 shares of the company's stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $475.34, for a total value of $251,930.20. Following the transaction, the executive vice president now directly owns 58,539 shares in the company, valued at approximately $27,825,928.26. This represents a 0.90% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP David Altshuler sold 3,231 shares of the business's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $500.00, for a total value of $1,615,500.00. Following the completion of the sale, the executive vice president now directly owns 26,512 shares in the company, valued at approximately $13,256,000. The trade was a 10.86% decrease in their position. The disclosure for this sale can be found here. Insiders sold 4,005 shares of company stock worth $1,978,465 over the last ninety days. Corporate insiders own 0.20% of the company's stock.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.